OraPharma returns US rights to Sinclair's Decapinol
This article was originally published in Scrip
More than two years after the planned launch of the prescription mouth rinse Decapinol (delmopinol) in the US, Sinclair Pharma has regained rights to its product from the Johnson & Johnson subsidiary OraPharma. Although an exclusive US licensing deal was signed in June 2006, when Sinclair said US sales would begin within 12 months, Decapinol is still not available in the US.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.